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Ribosomally synthesised and post-translationally modified pep-
tides (RiPPs) make up a wide group of natural compounds
with various biological activities.[1] The biosynthetic pathway of
RiPPs involves the action of many tailoring enzymes on a spe-
cific precursor peptide to yield the highly modified final prod-
uct. Cyanobactins are a large family of RiPPs that includes pa-
tellamides, ulithiacyclamides, and trunkamides (Scheme 1) and
that are produced by a diverse selection of cyanobacteria.[2]
Amongst the best-studied cyanobactins are the patellamides:
cyclic octapeptides produced by Prochloron didemni, the cya-
nobacterial symbiont of Lissoclinum patella. The biosynthetic
pathway of patellamides consists of a seven-gene cluster
(patA–G ; Figure 1) that encodes the precursor peptide (PatE) as
well as the altering enzymes. Common modifications of patell-
amides include heterocyclisation, oxidation, epimerisation and
macrocyclisation.[3]
Cyanobactins, including patellamides, have diverse and valu-
able biological activities.[2b] Patellamides B, C and D have
shown a reversal of the multidrug resistance seen for vinblas-
tine, colchicine and adriamycin treatment in the CEM/VLB100
human leukemic cell line,[4] and patellamide D is cytotoxic to-
wards fibroblast (MRC5V1) and bladder calcinoma (T24)
tumour cell lines.[5] However, the development of these com-
pounds requires large-scale synthesis in order to identify their
exact biological targets and ascertain structure–activity rela-
tionships to fine-tune their properties. The chemical synthesis
of such compounds is challenging, even more so (>16 syn-
Many natural cyclic peptides have potent and potentially
useful biological activities. Their use as therapeutic starting
points is often limited by the quantities available, the lack of
known biological targets and the practical limits on diversifica-
tion to fine-tune their properties. We report the use of en-
zymes from the cyanobactin family to heterocyclise and mac-
rocyclise chemically synthesised substrates so as to allow
larger-scale syntheses and better control over derivatisation.
We have made cyclic peptides containing orthogonal reactive
groups, azide or dehydroalanine, that allow chemical diversifi-
cation, including the use of fluorescent labels that can help in
target identification. We show that the enzymes are compati-
ble and efficient with such unnatural substrates. The combina-
tion of chemical synthesis and enzymatic transformation could
help renew interest in investigating natural cyclic peptides
with biological activity, as well as their unnatural analogues, as
therapeutics.
Scheme 1. Structures of cyanobactin metabolites.
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thetic steps) for those containing thiazoline and/or oxazoline
moieties.[6]
Biochemical studies have shown that PatGmac (macrocyclisa-
tion domain of PatG) tolerates significant diversity in the
amino acids in the core peptide,[8] as long as the core peptide
ends with a five-membered heterocyclic ring (either the natu-
rally occurring thiazoline/oxazoline motif or cis-proline) and is
flanked by a C-terminal macrocyclisation signature AYD.[9] More
recently, an engineered heterocyclase that can completely pro-
cess peptide substrates lacking the leader peptide has been re-
ported.[10] Taking advantage of this efficient biosynthetic ma-
chinery, we show that pairing chemical and enzymatic synthe-
ses is efficient for the generation of unnatural patellamide-like
cyclic peptides. We report herein the macrocyclisation of syn-
thetic peptides that contain unnatural amino acids by using
PatGmac as well as the selective derivatisation of the subse-
quent cyclic peptides. We also report the synthesis of a patell-
amide-like cyclic peptide containing both a heterocycle and an
unnatural amino acid in a one-pot procedure.
The introduction of bio-orthogonal or specific reacting
groups on the side chains of linear/cyclic peptide residues
would be highly desirable, as they would allow regiospecific
and facile derivatisation. This approach has been previously
used to study binding and/or activity,[11] to link a fluorescent
probe in order to investigate biological processes or pharma-
cokinetic behaviour,[12] and to connect other building blocks
for activity enhancement or drug delivery,[13] among others. Al-
though orthogonal reacting groups have been previously in-
troduced in vivo on precursor peptides of RiPPs through stop-
codon suppression (SCS) and supplementation-based incorpo-
ration (SPI),[14] these strategies lack the control for better selec-
tivity, specificity and flexibility that chemical synthesis permits.
Three patellamide-like cyclic peptides were made with either
an azidoalanine A(N3) or a dehydroalanine (Dha) reactive
group. The azide moiety is a well known bio-orthogonal group
that reacts with alkynes both ex and in vivo.[15] Although not
fully bio-orthogonal, Dha is extensively used for bioconju-
gation purposes.[16] The two groups, A(N3) and Dha, were intro-
duced at different positions (4 and 2, respectively) in their re-
spective core peptides to explore whether their incorporation
presented any challenges for PatGmac processing. For simplicity,
we made the first two compounds from peptides that lacked
any cysteine residues, and therefore heterocycles. Having es-
tablished a suitable approach, we advanced to adding the
azide to a cysteine-containing peptide. We were able to enzy-
matically heterocyclise the cysteine to a thiazoline within the
sequence and then macrocyclise the resulting product in a
one-pot process, to make a genuine patellamide analogue.
The synthetic precursor peptides 1 (ITAA(N3)ITAPAYD/G) and
3 (VDhaAGIGFPAYDG; Schemes S1–S2; Figures S2–S5 in the
Supporting Information) were incubated in the presence of
PatGmac. The corresponding cyclic peptides cyclo(-ITAA(N3)IT-
AP-) (2) and cyclo(-VDhaAGIGFP-) (4) were obtained in 45 and
63% purified yield, respectively (Scheme 2). To prove their
macrocyclic structure, peptides 2 and 4 were extensively ana-
lysed by NMR spectroscopy and MS2 (Supporting Information).
Furthermore, the Dha group was found to be highly stable
under the macrocyclisation reaction conditions (Figures S31–
S32).
Purified cyclic peptide 2 was then reacted with cyclooctyne
5 in a copper-free, strain-promoted azide–alkyne cycloaddition
(Scheme 3).[17] The product, 6, was obtained in 95% yield. We
used the same procedure to treat 2 with cyclooctyne 7 (DBCO-
Cy5), which contains the fluorescent cyanine tag (Cy5;
Scheme 2), and the cyclic peptide–Cy5 conjugate 8 was ob-
tained in 30% yield.
The measured maximum absorbance (l=649 nm) and emis-
sion (l=671 nm) properties of conjugate 8 were in good
agreement with those of the parent Cy5 molecule (Figure S33).
As these types of compounds could potentially be used for
target identification by fluorescence microscopy, conjugate 8
(dark blue colour) was tested to ensure there was no unex-
pected behaviour (such as quenching or precipitation) in cells.
When incubated with permeabilised HeLa cells, a diffuse stain-
ing pattern of 8 (red colour) throughout the cytoplasm and
nucleus was visualised by fluorescent microscopy (Figure 2);
this showed that the molecule behaves as expected in biologi-
cal buffers.
Figure 1. A) The pat gene cluster codes for PatA, which cleaves N-terminal
to core peptide, PatB and PatC (unknown function), PatD, which heterocy-
clases cysteine (serine, threonine) residues in the core peptide, PatE (precur-
sor peptide), PatF (inactive prenylase[7]) and PatG, which cleaves and macro-
cyclises to the core peptide and oxidises thiazolines. B) PatE precursor pep-
tide with its key regions highlighted.
Scheme 2. Macrocyclisation of the unnatural amino acid-containing precur-
sor peptides 1 and 3 with PatGmac affords cyclic peptides 2 (45% yield) and
4 (63% yield). a) PatGmac, 37 8C, pH 8.1
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Cyclic peptide 4 underwent a thio-Michael addition with the
cysteine-containing glutathione peptide 9 (Scheme 4) with an
excess of triethylamine in water and methanol.[18] The corre-
sponding compound 10 was obtained in 43% yield. Following
the successful addition of glutathione, we investigated wheth-
er the reaction could be carried out directly after the macro-
cyclisation reaction as a one-pot process. Once peptide 3 has
been fully macrocyclised, 100 equivalents of mercaptoethanol
were directly added into the reaction mixture, and this was left
at 37 8C overnight. The reaction was judged to be complete by
MS, and the final compound 11 was obtained in 60% yield.
The final product purifies as two separable peaks, which we at-
tribute to different diastereoisomers (Figure S34).
As PatGmac processes substrates with unnatural amino acids
at similar rates to other sequences,[9] we next tested the feasi-
bility of introducing heterocycles into such unnatural sub-
strates. The proline residue in peptide 1 was replaced with a
cysteine (peptide 12) that could be enzymatically heterocy-
clised. Like PatGmac, the heterocyclase enzymes of the cyano-
bactin pathways (known as the D enzymes)[3a,19] have been
shown to be tolerant of a wide range of sequences within the
core peptide.
We incubated peptide 12 overnight with the engineered
heterocyclase LynDfusion (from the aestuaramide pathway
(Lyngbya sp.)) in the presence of ATP and MgCl2. The fully het-
erocyclysed product 13 was detected by MS but not isolated
(Scheme 5; Figures S35–S36). Subsequent addition of PatGmac
Scheme 3. Copper-free azide–alkyne cycloaddition of 2 with strained cyclooctynes affords conjugates 6 (95% yield) and 8 (30% yield). a) CH3CN, H2O.
Figure 2. A) DMSO control nucleus stained with Dapi (blue) ; B) Cyclic pep-
tide 8 visualised in fixed permeabilised HeLa cells (red; pink when over-
lapped with nucleus). Scale bars : 5 mm.
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to the reaction mixture afforded the patellamide-like analogue
14 cyclo(-ITAA(N3)ITA
hetC-) in 58% yield.[20]
Milligram quantities of cyanobactin derivatives with fluores-
cent components will greatly facilitate the target identification
of many of these natural biologically active products.[2b] Target
identification will not only provide a basis for redesign of the
natural product but could also disclose new opportunities for
therapy. The expense and complexity of these labels means in
practical terms that they are better introduced late in the syn-
thesis. In the case of macrocyclic peptides, this means ideally
after the macrocycle is made. Introducing chemical diversity to
probe or fine tune the pharmacokinetic and biological proper-
ties of natural products is likewise most desirable when per-
formed as a final step on a common scaffold.
We have demonstrated that both the heterocyclases and
macrocyclases from the patellamide (and a related) pathway
can be used in vitro with entirely synthetic substrates that con-
tain such chemically reactive unnatural amino acids. Moreover,
we have shown that the resulting macrocycles can be deriva-
tised with high efficiency. The ability to combine the diversity
of chemical synthesis with the exquisite catalysis of enzymes is
well known and recognised to be powerful in developing natu-
ral products into therapeutics.[21] This approach can be extend-
ed to peptidic macrocycles and might likewise enable their fur-
ther development.
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Scheme 4. Thio-Michael addition of thiol derivatives to cyclic peptide 4. a) Et3N, H2O/MeOH (43%); b) Enzymatic reaction, bicine/NaCl buffer (pH 8.1), 37 8C
(60%).
Scheme 5. One-pot heterocyclisation with LynDfusion and macrocyclisation
with PatGmac for the synthesis of the unnatural patellamide 14. a) LynDfu-
sion, 27 8C, pH 9; b) PatGmac, 27 8C, pH 8.1.
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